STAGE IIC PROSTATE CANCER AJCC V8
Clinical trials for STAGE IIC PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIC PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIC PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a targeted pill boost prostate cancer control after radiation?
Disease control Recruiting nowThis study tests whether adding the drug niraparib to standard hormone therapy after radiation can better control high-risk prostate cancer that hasn't spread far. About 200 men will receive either hormone therapy alone or hormone therapy plus niraparib for up to a year. The goal…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 09, 2026 04:33 UTC
-
Shorter radiation may be safer for recurrent prostate cancer
Disease control Recruiting nowThis study tests whether a precise, short-course radiation therapy (SBRT) works as well as a slightly longer radiation schedule for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 men will receive either SBRT or hypofractionated radiation…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
Hormone boost may help scanners spot hidden prostate cancer
Diagnosis Recruiting nowThis study tests whether taking a short course of hormone therapy (relugolix) before a PSMA PET/CT scan can make the scan better at finding prostate cancer that has spread to lymph nodes. About 30 men with high-risk prostate cancer will receive the hormone drug for 5, 10, or 15 d…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated May 08, 2026 12:02 UTC
-
Heart-Smart prostate cancer treatment? new study pits relugolix against leuprolide
Knowledge-focused Recruiting nowThis study compares two hormone therapies—relugolix and leuprolide—given alongside radiation for prostate cancer. The goal is to see which drug has less impact on heart function. About 70 men with intermediate-risk prostate cancer will take one of the drugs for 6 months and under…
Matched conditions: STAGE IIC PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated May 07, 2026 18:42 UTC